Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction

Cancer Chemotherapy and Pharmacology · Published 2026-05-20 · DOI 10.1007/s00280-026-04900-1

Authors (2)

Ji-Hun Jang, Seung-Hyun Jeong

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Jang, J., Jeong, S. (2026). Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04900-1

Related articles

• Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Temozolomide resistance in glioma: aligning target discovery with clinically achievable CNS exposures and translational delivery strategies · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Transfer of trastuzumab and pertuzumab into human breast milk: a case report · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Synergistic anti-tumor activity of andrographolide and gemcitabine in intrahepatic cholangiocarcinoma through inhibition of RRM2 and the JAK/STAT3 pathway · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Successful oral desensitization to temozolomide in a patient with immediate hypersensitivity reaction · Cancer Chemotherapy and Pharmacology · 2026 · Same journal